PDRN Sensitization Testing: Methods, Standards, and Safety Evaluation for Nucleotide-Based Biomateri

PDRN sensitization testing is a critical safety evaluation for polydeoxyribonucleotide-based raw materials, injectables, cosmetics, and medical devices, confirming that these products do not induce delayed-type hypersensitivity reactions. This technical guide outlines the regulatory framework, sample requirements, in vitro and in vivo test methods, and practical considerations for assessing the sensitization potential of PDRN. Whether you are preparing an NMPA, CE, or cosmetic safety dossier, a well-designed sensitization testing strategy helps accelerate compliant product development.

Technical Overview

PDRN (polydeoxyribonucleotide) is a linear polymer of deoxyribonucleotides, typically with a molecular weight ranging from approximately 50 kDa to 1,500 kDa, derived from purified salmon or trout DNA. It is widely used in regenerative medicine, wound healing, and aesthetic applications due to its documented activity in promoting tissue repair, angiogenesis, and cellular proliferation, largely mediated through adenosine A2A receptor activation. Commercial formats include injectable skin boosters, mesotherapy solutions, topical serums, hydrogels, wound dressings, and porous scaffolds.

Sensitization testing evaluates the potential of a PDRN-based product to induce Type IV delayed contact hypersensitivity, a T-cell mediated immune response that develops after repeated exposure. Although high-molecular-weight polynucleotides are generally considered to have low inherent sensitizing potential, immunological risk can arise from residual proteins and peptides from the biological source, residual solvents and reagents from extraction and purification, depolymerized low-molecular-weight fragments, degradation products, and formulation excipients. Consequently, sensitization testing of the finished product or its extracts is a mandatory component of biological safety evaluation under medical device biocompatibility standards such as ISO 10993-10 and GB/T 16886.10, as well as cosmetic safety assessment frameworks worldwide.

A modern sensitization assessment for PDRN products typically combines in vitro assays addressing the key molecular events of skin sensitization (the adverse outcome pathway), supplemented where necessary by in vivo methods such as the Local Lymph Node Assay (LLNA) or Guinea Pig Maximization Test (GPMT), and completed by human confirmatory patch testing for finished cosmetic formulations.

Testing Samples

PDRN Raw Materials

Sodium polydeoxyribonucleotide powders and lyophilized intermediates submitted for characterization testing. Testing at the raw material stage supports supplier qualification, incoming quality control, and comparative evaluation of different purification grades. Key pretreatment steps include dissolution in physiological saline or culture medium at defined concentrations, verification of pH and osmolality, and confirmation of polymer integrity by molecular weight distribution analysis.

PDRN Injectable Solutions and Skin Boosters

Sterile, ready-to-use PDRN solutions intended for intradermal or subcutaneous administration. Because these products contact breached or compromised tissue directly, sensitization testing is performed alongside cytotoxicity, irritation, systemic toxicity, pyrogen, and hemocompatibility evaluations as part of a full biological safety program per ISO 10993-1.

PDRN-Containing Cosmetics

Finished cosmetic and functional skincare products such as ampoules, serums, creams, sheet masks, and meso-care formulations containing PDRN as an active or functional ingredient. These products are typically tested as the finished formulation to capture the combined sensitization potential of PDRN, excipients, preservatives, and fragrance components.

PDRN Medical Devices and Biomaterials

Wound dressings, hydrogels, microneedle patches, and tissue engineering scaffolds incorporating PDRN. For devices that cannot be dosed directly, sensitization testing is conducted on polar and non-polar extracts prepared according to ISO 10993-12 using exaggerated extraction conditions.

Testing Items

A comprehensive PDRN sensitization assessment typically covers the following items, selected according to product type, contact category, and target regulatory market:

• Skin sensitization potential (hazard identification: sensitizer or non-sensitizer)
• Delayed-type hypersensitivity (Type IV) response evaluation
• Key Event 1 assessment: molecular initiating event via peptide reactivity
• Key Event 2 assessment: keratinocyte inflammatory response
• Key Event 3 assessment: dendritic cell activation and co-stimulatory marker expression
• Polar and non-polar extract testing for medical device configurations
• Complementary adjacent evaluations frequently tested in parallel: cytotoxicity (ISO 10993-5), skin irritation (ISO 10993-23), and bacterial endotoxin screening

Testing Methods

In Vitro Sensitization Assays

In vitro methods form the first tier of a modern testing strategy and are aligned with the adverse outcome pathway for skin sensitization:

• DPRA (Direct Peptide Reactivity Assay, OECD TG 442C): quantifies reactivity of the test item with synthetic cysteine and lysine peptides by HPLC analysis, addressing the molecular initiating event. Solubility assessment is critical for high-molecular-weight PDRN samples, and aqueous dissolution is typically straightforward for sodium PDRN salts.
• ARE-Nrf2 luciferase assays, KeratinoSens or LuSens (OECD TG 442D): measure activation of the antioxidant response element pathway in transfected keratinocyte cells, addressing the keratinocyte response key event.
• h-CLAT, U-SENS, or IL-8 Luc assays (OECD TG 442E): measure upregulation of CD86 and CD54 surface markers or IL-8 release in monocytic cell lines, addressing dendritic cell activation.
• Defined approaches combining data from multiple in vitro methods (for example, the 2-out-of-3 approach described in OECD TG 497) enable animal-free hazard classification for many product categories.

In Vivo Sensitization Tests

In vivo methods may be required for certain regulatory submissions or when in vitro data are inconclusive:

• Local Lymph Node Assay (LLNA, OECD TG 429): measures lymphocyte proliferation in draining lymph nodes of mice following ear exposure; a stimulation index of 3 or above indicates sensitization. The reduced LLNA protocol can be used for confirmatory testing when a negative outcome is expected.
• Guinea Pig Maximization Test (GPMT, OECD TG 406): a two-phase induction and challenge design with Freund's complete adjuvant, suitable for medical device extracts per ISO 10993-10.
• Buehler test (OECD TG 406): an epidermal, adjuvant-free guinea pig method, applicable when irritation-based induction is more representative of exposure conditions.

Human Confirmatory Testing

For finished cosmetic formulations, the Human Repeat Insult Patch Test (HRIPT) provides direct clinical confirmation. The design typically involves an induction phase of repeated occlusive patch applications over three weeks, a rest period, and a challenge application, with dermal responses graded according to standardized scoring scales.

Sample Preparation and Extraction

For soluble PDRN products, direct dosing of aqueous stock solutions into assay systems is standard, with concentration ranges selected to avoid cytotoxicity-related false positives. For medical devices and composite materials, polar extraction in 0.9% sodium chloride and non-polar extraction in sesame oil is performed under exaggerated conditions, commonly 37 degrees Celsius for 72 hours, with a surface-area-to-volume ratio of 3 cm2/mL or a mass-to-volume ratio of 0.2 g/mL as appropriate to the device geometry.

Applications

PDRN sensitization testing data support a broad range of development and regulatory objectives:

• Biological evaluation reports for medical device registration submissions in China (NMPA), the European Union (MDR technical documentation), and other major markets
• Safety assessment dossiers and Product Information Files for cosmetic products containing PDRN under the EU Cosmetic Regulation and equivalent national frameworks
• Drug development safety packages for injectable PDRN formulations intended for parenteral administration
• Supplier qualification, incoming material control, and comparability studies during process scale-up or purification route changes
• Formulation screening to compare candidate excipient systems and preservative packages
• Post-market surveillance support and investigation of adverse event reports involving suspected allergic reactions

FAQ

Q: Is PDRN itself a known skin sensitizer?

A: Purified high-molecular-weight PDRN is generally regarded as having low inherent sensitization potential. In practice, positive or equivocal findings are more often attributable to residual host-cell proteins, low-molecular-weight nucleotide fragments, residual reagents, or formulation excipients, which is why finished-product testing is recommended in addition to raw material evaluation.

Q: Can sensitization assessment rely entirely on in vitro methods?

A: For many cosmetic and chemical safety frameworks, defined approaches combining DPRA, KeratinoSens, and h-CLAT data are accepted for hazard classification without animal testing. For medical devices, ISO 10993-10 permits in vitro alternatives with appropriate scientific justification, although some regulatory authorities and novel material categories may still request LLNA or GPMT data.

Q: How are test samples for PDRN devices prepared?

A: Devices are extracted in polar and non-polar vehicles per ISO 10993-12 under exaggerated conditions. Because sodium PDRN is highly water soluble, polar extraction efficiently recovers the active polymer, while non-polar extraction addresses potential leachables from device components and packaging.

Q: What is a typical project timeline?

A: In vitro assays generally require 2 to 6 weeks including solubility and cytotoxicity range-finding work. LLNA studies require approximately 6 weeks, GPMT studies approximately 8 to 10 weeks, and HRIPT studies approximately 10 to 12 weeks including panel recruitment and reporting.

Q: What are the acceptance criteria for a negative result?

A: In the LLNA, a stimulation index below 3 with no evidence of systemic toxicity supports a non-sensitizer classification. In GPMT and Buehler studies, the absence of sensitization responses in test animals exceeding vehicle controls indicates a non-sensitizing result. In vitro defined approaches classify outcomes as sensitizer or non-sensitizer according to the prediction models specified in the respective OECD test guidelines.

Q: What additional tests should accompany sensitization evaluation for injectable PDRN products?

A: For parenterally administered products, a full ISO 10993-1 biological evaluation is expected, including cytotoxicity, irritation, acute systemic toxicity, pyrogen and endotoxin testing, hemocompatibility, and, where applicable, subacute or subchronic toxicity and genotoxicity studies.